



Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting

April 26, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois on June 1-5, 2018. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.

Poster Presentations at ASCO:

Title: **Erythropoietic Cellular Analyses in Luspatercept-Treated Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study** (Abstract: #7018)

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Date: Monday, June 4th

Time: 11:30 a.m. – 12:45 p.m. CDT (McCormick Place, E450)

Title: **A Phase 2, Multicenter, Open-Label Study of the Safety and Efficacy of Luspatercept in Subjects with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis and Anemia With or Without RBC Transfusion Dependence** (Abstract: #TPS7083)

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Date: Monday, June 4th

Time: 8:00 a.m. – 11:30 a.m. CDT (McCormick Place, Hall A)

The MDS Phase 2 poster presentation at the conference will include updated information beyond that included in the abstract available on the ASCO conference website on May 16, 2018. The clinical posters will be available immediately following the presentations at the conference on June 4, 2018 in the "Science" section on Acceleron's website, www.acceleronpharma.com.

About Luspatercept

Luspatercept is a first-in-class erythroid maturation agent (EMA) that regulates late-stage red blood cell maturation. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the MEDALIST trial) and in patients with beta-thalassemia (the BELIEVE trial). A Phase 3 trial is being planned in first-line, lower-risk, myelodysplastic syndromes patients (the COMMANDS trial). The BEYOND Phase 2 trial in non-transfusion-dependent beta-thalassemia and a Phase 2 trial in myelofibrosis are ongoing. For more information, please visit www.clinicaltrials.gov.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on social media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

Forward-Looking Statements

This press release contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company's compounds and the expected timing for reporting of data from ongoing clinical trials. The words "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results could differ materially from those included in the forward-looking statements due to various risks and uncertainties, including, but not limited to, that preclinical testing of the Company's compounds and data from clinical trials may not be predictive of the results or success of ongoing

or later clinical trials, that the development of the Company's compounds will take longer and/or cost more than planned, that the Company or its collaboration partner, Celgene, will be unable to successfully complete the clinical development of the Company's compounds, that the Company or Celgene may be delayed in initiating, enrolling or completing any clinical trials, and that the Company's compounds will not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, and other filings that the Company has made and may make with the SEC in the future.

The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions and projections with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180426005278/en/>

Source: Acceleron Pharma Inc.

Acceleron Pharma Inc.

Todd James, IRC, (617) 649-9393

Vice President, Investor Relations and Corporate Communications

or

Candice Ellis, 617-649-9226

Manager, Investor Relations and Corporate Communications

or

Media:

BMC Communications

Brad Miles, 646-513-3125